Original Article

You have full text access to this OnlineOpen article

Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

  1. M F Fromm,
  2. D Busse,
  3. H K Kroemer,
  4. M Eichelbaum

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510240407

Issue

Hepatology

Hepatology

Volume 24, Issue 4, pages 796–801, October 1996

Additional Information

How to Cite

Fromm, M. F., Busse, D., Kroemer, H. K. and Eichelbaum, M. (1996), Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology, 24: 796–801. doi: 10.1002/hep.510240407

Author Information

  1. Dr. Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Stuttgart, Germany

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (225K)

References

  • 1
    Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029–1036.
  • 2
    Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871–1878.
  • 3
    Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM. et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247–259.
  • 4
    Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994; 22: 947–955.
  • 5
    De Waziers I, Cugnenc PH, Yang CS, Leroux J-P, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387–394.
  • 6
    Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–160.
  • 7
    Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–1490.
  • 8
    Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453–457.
  • 9
    Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15–19.
  • 10
    Eichelbaum M, Dengler HJ, Somogyi A, von Unruh GE. Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Eur J Clin Pharmacol 1981; 19: 127–131.
  • 11
    Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992; 260: 1052–1057.
  • 12
    Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf R, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 332–337.
  • 13
    Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 20 subfamily are the major enzymes involved in the O-demeth-ylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353: 116–121.
  • 14
    Echizen H, Brecht T, Niedergesass S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 1985; 109: 210–217.
  • 15
    Echizen H, Vogelgesang B, Eichelbaum M. Effects of d, l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 1985; 38: 71–76.
  • 16
    Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Int Med 1992; 152: 711–716.
  • 17
    Rieder HL, Cauthen GM, Kelly GD, Bloch AB, Snider DE. Tuberculosis in the United States. JAMA 1989; 262: 385–389.
  • 18
    Rahn KH, Mooy J, Böhm R, Von de Vet A. Reduction of bioavailability of verapamil by rifampin. N Engl J Med 1985; 312: 920–921.
  • 19
    Barbarash RA. Verapamil-rifampin interaction. Drug Intell Clin Pharm 1985; 19: 559–560.
  • 20
    Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin. Chest 1988; 94: 954–959.
  • 21
    Fischer C, Schonberger F, Mück W, Heuck K, Eichelbaum M. Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography-mass spectroscopy combined with a stable isotope technique. J Pharm Sci 1993; 82: 244–250.
    Direct Link:
  • 22
    Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther 1990; 253: 1042–1048.
  • 23
    Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and applications. Philadelphia: Lea & Febiger, 1995.
  • 24
    Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res 1976; 10: 1–8.
  • 25
    Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OFW. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297–301.
    Direct Link:
  • 26
    Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M. Pharmacokinetics, bioavailability and EGG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981; 12: 51–60.
  • 27
    Gross AS, Heuer B, Eichelbaum M. Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol 1988; 37: 4623–4627.
  • 28
    Ohnhaus EE, Coninx S, Ramos MR, Noelpp U. Liver blood flow and enzyme induction in man. Br J Clin Pharmacol 1976; 3: 352–353.
  • 29
    Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 1982; 22: 441–445.
  • 30
    Bauer LA, Stenwall M, Horn JR, Davis R, Opheim K, Greene L. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther 1986; 40: 239–242.
  • 31
    Meredith PA, Elliott HL, Pasanisi F, Kelman AW, Sumner DJ, Reid JL. Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol 1985; 20: 101–106.
  • 32
    Bolondi L. The value of Doppler US in the study of hepatic hemodynamics. Consensus conference. J Hepatol 1990; 10: 353–355.
  • 33
    Reiss WG, Bauer LA, Horn JR, Zierler BK, Easterling TR, Strandness DE. The effects of oral nifedipine on hepatic blood flow in humans. Clin Pharmacol Ther 1991; 50: 379–384.
  • 34
    McDonnell WM, Scheiman JM, Traber PG. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 1992; 103: 1509–1516.
  • 35
    Morel F, Beaune PH, Ratanasavanh D, Flinois J-P, Yang CS, Guengerich FP, Guillouzo A. Expression of cytochrome P-450 enzymes in cultured human hepatozytes. Eur J Biochem 1990; 191: 437–444.
    Direct Link:
  • 36
    Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285–299.
  • 37
    Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wschr 1985; 63: 1205–1211.
  • 38
    Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485–491.
  • 39
    Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298–305.
  • 40
    Eichelbaum M, Somogyi A, Unruh GEv, Dengler HJ. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol 1981; 19: 133–137.
  • 41
    Woodcock BG, Schulz W, Kober G, Rietbrock N. Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther 1981; 30: 52–56.
  • 42
    Eichelbaum M, Albrecht M, Kliems G, Schäfer K, Somogyi A. Influence of mesocaval shunt surgery on verapamil kinetics, bioavailability and response. Brit J Clin Pharmacol 1980; 10: 527–530.
  • 43
    Ariëns EJ. Nonchiral, homochiral and composite chiral drugs. Trends Pharmacol Sci 1993; 14: 68–75.
  • 44
    Kroemer HK, Fromm MF, Buhl K, Terefe H, Blaschke G, Eichelbaum M. An enantiomer-enantiomer interaction of (S)-and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 1994; 89: 2396–2400.
  • 45
    Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. Br J Clin Pharmacol 1991; 32: 735–739.
  • 46
    Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6β-hy-droxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989; 36: 39–46.
  • 47
    Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992; 41: 1047–1055.
Get PDF (225K)